Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB106385 Monotherapy or with Retifanlimab in Advanced Solid Tumors
NCT04580485Phase 1Completed
- Sponsor
- Incyte
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of INCB106385 in ovarian cancer, bladder cancer, non-small cell lung cancer (NSCLC) and 9 more (2 arms), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events up to 28 months. Started Feb 2021; status: completed.
02
Drugs
INCB106385
03
Conditions
ovarian cancerbladder cancernon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04580485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580485.